Document is current
Any future updates will be listed below
-
Authors
Liu, Dan
Gong, Jifang
Zhang, Jian
Shu, Yongqian
Wu, Hao
Liu, Tianshu
Xu, Yanhua
Zhang, Lijia
Li, Min
Hu, Xichun
Shen, Lin
-
Funding
Funding for this research was provided by:
Ningbo Newbay Pharmaceutical Technology Co., Ltd (n/a)
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 28 January 2025
First Online: 20 February 2025
Declarations
:
: The trial was conducted in adherence to the principles outlined in the Declaration of Helsinki and the guidelines of Good Clinical Practice (GCP). Ethical approval for the protocol was obtained from the ethics committees of Beijing Cancer Hospital, along with each of the participating centers, under the approval numbers 2018L02782, 2018L02783, and 2018L02784. Prior to the commencement of any procedures, all participating patients provided their written informed consent.
: Not applicable.
: The authors declare no competing interests.
